These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Single and multiple dose pharmacokinetics of tenoxicam in the elderly. Nilsen OG; Walstad RA; Eckert M; Heizmann P; Bückert A; Am T; Løge I; Unnvik J; Thue E Eur J Clin Pharmacol; 1988; 35(5):563-6. PubMed ID: 3266152 [TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers. Nilsen OG; Aasarød K; Widerøe TE; Guentert TW Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981 [TBL] [Abstract][Full Text] [Related]
6. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. Day RO; Geisslinger G; Paull P; Williams KM Br J Clin Pharmacol; 1994 Jan; 37(1):79-81. PubMed ID: 8148224 [TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. Day RO; Williams KM; Graham S; Handel M Arthritis Rheum; 1991 Jun; 34(6):751-60. PubMed ID: 2053921 [TBL] [Abstract][Full Text] [Related]
12. The influence of cholestyramine on the elimination of tenoxicam and piroxicam. Guentert TW; Defoin R; Mosberg H Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866 [TBL] [Abstract][Full Text] [Related]
13. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878 [TBL] [Abstract][Full Text] [Related]
14. Tenoxicam i.v. in major gynaecological surgery--pharmacokinetic, pain relief and haematological effects. Jones RD; Miles W; Prankerd R; Lang C; Chilvers M; Lo SK Anaesth Intensive Care; 2000 Oct; 28(5):491-500. PubMed ID: 11094663 [TBL] [Abstract][Full Text] [Related]
15. Effects of tenoxicam on renal function and the disposition of inulin and p-aminohippurate in healthy volunteers and patients with chronic renal failure. Freestone S; McAuslane JA; Prescott LF Br J Clin Pharmacol; 1991 Oct; 32(4):495-500. PubMed ID: 1958445 [TBL] [Abstract][Full Text] [Related]
16. Tenoxicam concentrations in synovium and joint cartilage in humans. Bannwarth B; Netter P; Lapicque F; Mainard D; Fener P; Gillet P; Gaucher A Agents Actions; 1991 Mar; 32(3-4):295-8. PubMed ID: 1862747 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of tenoxicam at different dosage regimes. Scaglione F; Demartini G; Dugnani S; Fraschini F; Triscari FA Farmaco; 1993 Sep; 48(9):1321-5. PubMed ID: 8259988 [TBL] [Abstract][Full Text] [Related]
18. Absence of interaction between tenoxicam and warfarin. Eichler HG; Jung M; Kyrle PA; Rotter M; Korn A Eur J Clin Pharmacol; 1992; 42(2):227-9. PubMed ID: 1618257 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. Ji HY; Lee HW; Kim YH; Jeong DW; Lee HS J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 826(1-2):214-9. PubMed ID: 16169293 [TBL] [Abstract][Full Text] [Related]
20. Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. Hinderling PH; Hartmann D; Crevoisier C; Moser U; Heizmann P Ther Drug Monit; 1988; 10(3):250-60. PubMed ID: 3262939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]